The plasma pharmacokinetics, tissue distribution, excretion and binding to plasma proteins of vinflunine, were investigated after intravenous (iv) administration. We obtained plasma profiles after iv administration of vinflunine at the doses of 3.5, 7 and 14 mg/kg in rats. The t1/2 values for vinflunine were estimated to be 18.38±1.20, 17.05±0.77, 18.35±1.57 h, and the mean AUC0−t, values were 3.48±0.38, 6.54±0.68, 12.79±2.93 μg-h/ml, respectively. Of the various tissues tested, vinflunine was widely distributed into tissues, with the highest concentrations of vinflunine being found in well perfused organs. Maximal concentration of vinflunine was reached at 0.5 h postdose in the majority of tissues. In tumor-bearing mice, the similar pattern of tissue distribution was observable, except that vinflunine can be distributed into tumor. The binding of vinflunine in human and rat plasma proteins were 39.6% and 58.4% respectively. Within 96 h after administration, 9.58%, 15.36% and 0.71% of the given dose was excreted in urine, feces and bile, respectively. In conclusion, Vinflunine had a longer terminal half-life, a wide tissue distribution and less than 25% of the given dose was excreted as unchanged drug, suggesting metabolism as a major style of elimination.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Donehover R.C., Rowinsky E.K., Devita V.T., Hellman S., Rosenberg S.A. (1993). In Cancer: Principles and Practice of Oncology, JB Lippincott Co., Philadelphia, PA, 409–417.
Jordan M.A., Thrower D., Wilson L (1991): Mechanism of inhibition by Vinca alkaloids. Cancer Res., 51, 2212–2222.
Wilson L., Panda D., Jordan M.A. (1999): Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct., 24, 329–335.
Fahy J., Duflos A., Ribet J.P. (1997): Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J. Am. Chem. Soc., 119, 8576–8577.
Bunn. P.A. Jr., Kelly K. (1998): New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 4, 1087–1100.
Crown J. (1997): Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer. Eur. J. Cancer, 33 suppl. 7, S15-S19.
Johnson S.A., Harper P., Hortobagyi G.N., Pouillart P. (1996): Vinorelbine: an overview. Cancer Treat. Rev., 22, 127–142.
Jordan M.A., Wilson L. (1990): Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry, 29, 2730–2739.
Kruczynski A., Barret J.M., Etievant C, Colpaert F., Fahy J., Hill B.T. (1998): Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol., 55, 635–648.
Kruczynski A., Colpaert F., Tarayre J.P., Mouillard P., Fahy J., Hill B.T. (1998): Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol., 41, 437–447.
Hill B.T., Fiebig H.H., Waud W.R., Poupon M.F., Colpaert F., Kruczynski A. (1999): Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer, 35, 512–520.
Kruczynski A., Hill B.T. (2001): Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol. Hematol., 40, 159–173.
Singer W.D., Himes R.H. (1992): Cellular uptake and tubulin binding properties of four Vinca alkaloids. Biochem. Pharmacol., 43, 545–551.
Holwell S.E., Hill B.T., Bibby M.C. (2001): Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer, 84, 290–295.
Bennouna J., Fumoleau P., Armand J.P., Raymond E., Campone M., Delgado F.M., Puozzo C., Marty M. (2003): Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann. of Oncol., 14, 630–637.
Etiévant C., Barret J.M., Kruczynski A. Perrin D. Hill B.T. (1998): Vinflunine (20′, 20′-difluoro-3′, 4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Inveat. New Drugs, 16, 3–17.
Jacquesy J.C., Jouannetaud M.P. (2005): Vinflunine: anew anti-cancer fluorinated agent derived from Vinca-alkaloids. Ann. Pharm. Fr., 63, 28–34.
About this article
Cite this article
Zhao, X., Liu, X., Wang, Y. et al. Pharmacokinetics, tissue distribution and excretion of vinflunine. European Journal of Drug Metabolism and Pharmacokinetics 31, 59–64 (2006). https://doi.org/10.1007/BF03191120
- tissue distribution